|
| Interventional Effect of Jianpi Bushen GranuleCombined with Western Medicine on the Level ofSerum Acetylcholine Receptor Antibodies inMyasthenia Gravis Patients |
| |
| View Full Text View/Add Comment Download reader |
| DOI：10.15806/j.issn.2311-8571.2015.0012 |
| KeyWord:Myasthenia gravis, JBG, AchRAb, ELISIA |
| Author | Institution |
| Chao Jiangab |
a.Department of Neurology, Xijing Hospital, the Fourth Military Medical University, Xi’an , PR China
b.Traditional Chinese Medicine Department of Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine, Shanghai , PR China |
| Ping Liub* |
b.Traditional Chinese Medicine Department of Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine, Shanghai , PR China |
| Jing-Sheng Zhangc |
c.Neurological Medical Department of the China Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang ,
PR China |
| Wen-Jing Baoc |
c.Neurological Medical Department of the China Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang ,
PR China |
| Yan Liangb |
b.Traditional Chinese Medicine Department of Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine, Shanghai , PR China |
| Shao-Bo Qiub |
b.Traditional Chinese Medicine Department of Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine, Shanghai , PR China |
| Lin Jiangd |
d.State Key Laboratory of Bioreactor Engineering & Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of
Science and Technology, Shanghai , PR China |
|
| Hits: 2525 |
| Download times: 2447 |
| Abstract: |
| Objective: This study is aimed to investigate the clinical significance of regulating effect of Jianpi Bushen Granule (JBG) combined with
Western medicine on the level of serum acetylcholine receptor antibodies (AchRAb) in myasthenia gravis (MG) patients, so as to offer a
theoretical basis of the targeted therapy with AchRAb.
Methods: We detected the level of anti-AchRAb with enzyme linked immunosorbent assay (ELISA) in the sera from 60 cases of MG patients
(randomly divided into the trial group 30 cases, control group 30) for before and after treatment 6 months, and the clinical evaluation carried
out by the Quantitative score of myasthenia gravis (QMG) for before and after treatment 3,6 months.
Results: (1) Comparison of the level of serum AchRAb:All included MG patients, the positive rate of serum AchRAb was about 81.67%
(49/60), and the trial group was 83.33% (25/30), the control group was 90% (27/30), and the serum AchRAb levels of the trial group (0.994 ±
0.417) was lower than that of the contral group (1.068 ± 0.358), but there was no significant difference between the two groups before
treatment (P > 0.05). After 6 months of treatment, the serum AchRAb levels of the trial group (0.721 ± 0.280) was also significantly lower than
that of the contral group (0.907 ± 0.387), and the serum AchRAb levels was decreased dramatically compared with the same group before
treatment, there was significant difference between the two groups (P < 0.05). (2)Comparison of QMG scoring:QMG scoring was decreased
dramatically in the trial group compared with that of the control group after treatment, there was significant difference (P < 0.05), moreover,
the total effective rate in the trial group (50%,86.67%)was significantly higher than those in the control groups (23.33%, 40%) after 3,6 months
treatment (P < 0.05). There was also significant difference in the clinical evaluation by the QMG between the two groups before and after
treatment. (3) Adverse reactions: no obvious adverse reactions appeared among the two groups.
Conclusions: JBG combined with Western medicine therapy on MG by regulating the level of patients’ serum AchRAb shows definite effects,
and it is worthy of further studying. |
| Close |
|
|
|